Artivion/$AORT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Artivion
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
Ticker
$AORT
Sector
Primary listing
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
1,600
ISIN
US2289031005
Website
Artivion Metrics
BasicAdvanced
$1.5B
-
-$0.53
1.54
-
Price and volume
Market cap
$1.5B
Beta
1.54
52-week high
$32.33
52-week low
$21.97
Average daily volume
340K
Financial strength
Current ratio
5.531
Quick ratio
2.569
Long term debt to equity
121.318
Total debt to equity
123.146
Interest coverage (TTM)
0.57%
Profitability
EBITDA (TTM)
47.582
Gross margin (TTM)
63.94%
Net profit margin (TTM)
-5.49%
Operating margin (TTM)
6.11%
Effective tax rate (TTM)
5.28%
Revenue per employee (TTM)
$240,000
Management effectiveness
Return on assets (TTM)
1.89%
Return on equity (TTM)
-7.26%
Valuation
Price to revenue (TTM)
3.454
Price to book
4.67
Price to tangible book (TTM)
-12.85
Price to free cash flow (TTM)
-77.267
Free cash flow yield (TTM)
-1.29%
Free cash flow per share (TTM)
-41.61%
Growth
Revenue change (TTM)
5.94%
Earnings per share change (TTM)
126.44%
3-year revenue growth (CAGR)
8.55%
10-year revenue growth (CAGR)
10.58%
3-year earnings per share growth (CAGR)
11.81%
10-year earnings per share growth (CAGR)
10.06%
What the Analysts think about Artivion
Analyst ratings (Buy, Hold, Sell) for Artivion stock.
Bulls say / Bears say
Artivion's revenue increased by 10% year-over-year to $98.0 million in Q2 2024, driven by strong performance across its product lines, indicating robust demand and effective market penetration. (marketinference.com)
The company reported a gross margin of 70.4% in 2024, reflecting strong pricing power and efficient cost management, which could lead to improved profitability. (dcfmodeling.com)
Artivion's AMDS Hybrid Prosthesis has demonstrated significant clinical benefits, including a 94% freedom from aortic reoperation and a 90% cerebral malperfusion resolution rate, potentially leading to increased adoption and revenue growth upon regulatory approval. (beyondspx.com)
Artivion reported a net loss of $16.5 million in Q4 2024, compared to a net income of $7.5 million in Q1 2024, indicating financial instability and potential challenges in achieving profitability. (marketbeat.com)
The company's debt-to-equity ratio stood at 1.18 as of September 30, 2024, suggesting a significant reliance on debt financing, which could pose risks in a rising interest rate environment. (beyondspx.com)
Artivion's stock valuation appears stretched, with a forward P/E ratio of 158.00, indicating that the stock may be overvalued relative to its earnings potential. (seekingalpha.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
Artivion Financial Performance
Revenues and expenses
Artivion Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Artivion stock?
Artivion (AORT) has a market cap of $1.5B as of July 10, 2025.
What is the P/E ratio for Artivion stock?
The price to earnings (P/E) ratio for Artivion (AORT) stock is 0 as of July 10, 2025.
Does Artivion stock pay dividends?
No, Artivion (AORT) stock does not pay dividends to its shareholders as of July 10, 2025.
When is the next Artivion dividend payment date?
Artivion (AORT) stock does not pay dividends to its shareholders.
What is the beta indicator for Artivion?
Artivion (AORT) has a beta rating of 1.54. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.